Verona Pharma(VRNA) - 2024 Q2 - Quarterly Results

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update Ohtuvayre (ensifentrine) now available; patient shipments started TM Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., August 8, 2024 – Verona Pharma plc (Nasdaq: VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the second quarter ...